Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain (Morpheus II)
This study has been completed.
Sponsor:
Bayer
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT01280591
First received: January 20, 2011
Last updated: November 19, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The objective of the study is to evaluate the efficacy and safety of a single oral dose of two dose combinations of naproxen sodium and diphenhydramine (DPH) to demonstrate that naproxen sodium/DPH combination provides added clinical benefit to sleep improvement than either single ingredient alone in subjects with post-surgical dental pain and phase advanced sleep.
| Condition | Intervention | Phase |
|---|---|---|
|
Pain, Postoperative |
Drug: BAY98-7111 Drug: Placebo Drug: Naproxen Sodium (Aleve, BAYH6689) Drug: Diphenhydramine |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep |
Resource links provided by NLM:
Drug Information available for:
Promethazine hydrochloride
Diphenhydramine
Promethazine
Diphenhydramine hydrochloride
Naproxen
Naproxen sodium
Diphenhydramine citrate
U.S. FDA Resources
Further study details as provided by Bayer:
Primary Outcome Measures:
- Wake time after sleep onset (WASO) measured by actigraphy [ Time Frame: 10 hours ] [ Designated as safety issue: No ]
- Sleep latency by measured by actigraphy [ Time Frame: 10 hours ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Total sleep time by Actigraphy [ Time Frame: 10 hours ] [ Designated as safety issue: No ]
- Sleep efficiency by Actigraphy [ Time Frame: 10 hours ] [ Designated as safety issue: No ]
- Subjective sleep variables [ Time Frame: 10 hours ] [ Designated as safety issue: No ]
- Overall rating of severity and change from baseline [ Time Frame: 10 hours ] [ Designated as safety issue: No ]
| Enrollment: | 733 |
| Study Start Date: | October 2010 |
| Study Completion Date: | February 2011 |
| Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: BAY98-7111 [440mg]
Two Naproxen sodium 220 mg/DPH (Diphenhydramine) 25 mg tablets
|
Drug: BAY98-7111
Naproxen sodium 220 mg/DPH 25 mg tablet combination
|
|
Experimental: BAY98-7111 [220mg] + Placebo
One Naproxen sodium 220 mg/DPH 50 mg tablet and one matching placebo capsule
|
Drug: BAY98-7111
Naproxen sodium 220 mg/DPH 50 mg tablet combination
Drug: Placebo
|
|
Active Comparator: Naproxen Sodium
Two Naproxen sodium 220 mg tablets
|
Drug: Naproxen Sodium (Aleve, BAYH6689) |
|
Active Comparator: Diphenhydramine
Two DPH 25 mg tablets
|
Drug: Diphenhydramine |
Eligibility| Ages Eligible for Study: | 12 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Healthy, ambulatory, male and female volunteers ages 12 and older
Scheduled to undergo surgical removal of a minimum of two third molars of which at least one has to be a mandibular third molar. The mandibular extraction(s) required by each subject must meet one of the following scenarios:
- one full bony impaction
- two partial bony impactions
- one full bony impaction and one partial bony impaction
- one full bony impaction and one soft tissue impaction
- one full bony impaction and one erupted third molar. Two full bony mandibular impactions are not allowed. Maxillary third molars may be removed regardless of impaction level.
- Have moderate to severe postoperative pain on the Categorical Pain Rating Scale and a score of ≥ 50 mm on the 100-mm visual analog Pain Severity Rating Scale between 1600 hour and 1830 hour on the day of surgery
- Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera, or double-barrier and have a negative pregnancy test at Screening and prior to surgery. Female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy
- Provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial, (subjects <18 years of age must sign a written assent and have parental or guardian consent).
Exclusion Criteria:
- History of hypersensitivity to naproxen, diphenhydramine, nonsteroidal anti-inflammatory drug (NSAIDS), tramadol, aspirin or any other antihistamine and similar pharmacological agents or components of the products
- Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years
- Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study in the judgment of the investigator
- Current or past history of bleeding disorder(s)
- Acute illness or local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator
- Chronic use of antihistamines defined as using 5 or more times a week for 2 or more consecutive weeks during the past 3 months
- Positive alcohol breathalyzer test and positive urine drug test prior to surgery
- Females who are pregnant or lactating
- Chronic or severe sleep problems that do not respond to / Over the Counter (OTC) medication and requires a prescription hypnotic or sedative
- Habitually spends less than 6.5 hours in bed
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Head Clinical and Medical Affairs, Bayer Healthcare LLC, Consumer Care |
| ClinicalTrials.gov Identifier: | NCT01280591 History of Changes |
| Other Study ID Numbers: | 14837 |
| Study First Received: | January 20, 2011 |
| Last Updated: | November 19, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Bayer:
|
Naproxen sodium Diphenhydramine |
Additional relevant MeSH terms:
|
Pain, Postoperative Toothache Postoperative Complications Pathologic Processes Pain Signs and Symptoms Tooth Diseases Stomatognathic Diseases Facial Pain Naproxen Diphenhydramine Promethazine Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Gout Suppressants Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Central Nervous System Agents Antiemetics Autonomic Agents Gastrointestinal Agents |
ClinicalTrials.gov processed this record on June 18, 2013